Fmr LLC Relmada Therapeutics, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Fmr LLC holds 90,359 shares of RLMD stock, worth $316,256. This represents 0.0% of its overall portfolio holdings.

Number of Shares

90,359

Previous 83,847 7.77%

Holding current value

$316,256

Previous $389,000 30.33%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$2.93 - $4.94 $19,080 - $32,169	6,512 Added 7.77%	90,359 $271,000
Q1 2024 May 13, 2024	SELL	$3.1 - $6.8 $933 - $2,046	-301 Reduced 0.36%	83,847 $389,000
Q4 2023 Feb 13, 2024	SELL	$2.45 - $4.22 $323 - $557	-132 Reduced 0.16%	84,148 $348,000
Q3 2023 Nov 13, 2023	SELL	$2.48 - $3.79 $667 - $1,019	-269 Reduced 0.32%	84,280 $252,000
Q2 2023 Aug 11, 2023	SELL	$2.22 - $3.54 $10,942 - $17,448	-4,929 Reduced 5.51%	84,549 $207,000
Q1 2023 May 11, 2023	BUY	$2.24 - $4.76 $12,819 - $27,241	5,723 Added 6.83%	89,478 $202,000
Q4 2022 Feb 13, 2023	BUY	$2.17 - $35.84 $180,437 - $2.98 Million	83,151 Added 13766.72%	83,755 $292,000
Q3 2022 Nov 10, 2022	BUY	$18.3 - $37.02 $7,063 - $14,289	386 Added 177.06%	604 $22,000
Q2 2022 Aug 12, 2022	SELL	$16.5 - $30.34 $247 - $455	-15 Reduced 6.44%	218 $4,000
Q1 2022 May 13, 2022	BUY	$16.72 - $26.99 $3,561 - $5,748	213 Added 1065.0%	233 $6,000
Q4 2021 Feb 14, 2022	BUY	$16.93 - $26.82 $338 - $536	20 New	20 $0

Others Institutions Holding RLMD

# of Institutions

Shares Held

13.5M

Call Options Held

85.8K

Put Options Held

42.8K

View Full List

About RELMADA THERAPEUTICS, INC.

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $100M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

More about RLMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account